MA53643A - Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 - Google Patents

Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Info

Publication number
MA53643A
MA53643A MA053643A MA53643A MA53643A MA 53643 A MA53643 A MA 53643A MA 053643 A MA053643 A MA 053643A MA 53643 A MA53643 A MA 53643A MA 53643 A MA53643 A MA 53643A
Authority
MA
Morocco
Prior art keywords
dioxocyclobutenylamino
picolinamide
hydroxy
substituted
useful
Prior art date
Application number
MA053643A
Other languages
English (en)
Inventor
Andrew Christopher Flick
Brian Stephen Gerstenberger
Daniel Wei-Shung Kung
Vincent Michael Lombardo
James John Mousseau
Philippe Marcel Nuhant
Jr Ralph Pelton Robinson
Daniel Copley Schmitt
Mark Edward Schnute
Atli Thorarensen
John Isidro Trujillo
Rayomand Jal Unwalla
Huixian Wu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA53643A publication Critical patent/MA53643A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA053643A 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 MA53643A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734486P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MA53643A true MA53643A (fr) 2021-12-29

Family

ID=68051869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053643A MA53643A (fr) 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Country Status (32)

Country Link
US (3) US10975065B2 (fr)
EP (1) EP3852879A1 (fr)
JP (1) JP6989729B2 (fr)
KR (2) KR102755257B1 (fr)
CN (2) CN116874466B (fr)
AR (1) AR116464A1 (fr)
AU (1) AU2019344107B2 (fr)
BR (1) BR112021003956A2 (fr)
CA (1) CA3055805A1 (fr)
CL (1) CL2021000683A1 (fr)
CO (1) CO2021003391A2 (fr)
CR (1) CR20210146A (fr)
CU (1) CU20210016A7 (fr)
DO (1) DOP2021000045A (fr)
EA (1) EA202190586A1 (fr)
EC (1) ECSP21018584A (fr)
GE (2) GEP20237476B (fr)
IL (1) IL281634B2 (fr)
MA (1) MA53643A (fr)
MX (1) MX2021003318A (fr)
MY (1) MY209296A (fr)
NI (1) NI202100012A (fr)
NZ (1) NZ773473A (fr)
PE (1) PE20211070A1 (fr)
PH (1) PH12021550554A1 (fr)
PY (1) PY1978496A (fr)
SG (1) SG11202101827RA (fr)
TW (1) TWI754172B (fr)
UA (1) UA128700C2 (fr)
UY (1) UY38379A (fr)
WO (1) WO2020058869A1 (fr)
ZA (1) ZA202101169B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211070A1 (es) 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
TWI904157B (zh) 2020-04-30 2025-11-11 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
JP2024539987A (ja) 2021-10-26 2024-10-31 イドルシア・ファーマシューティカルズ・リミテッド Ｃｃｒ６受容体調節剤
ES3073199T3 (en) * 2021-10-28 2026-07-09 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN116162081B (zh) * 2022-12-13 2024-08-09 药康众拓(江苏)医药科技有限公司 一类氘代吡啶酰胺类ccr6抑制剂药物及用途
KR20260005351A (ko) * 2023-04-28 2026-01-09 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 Ccr6 길항제로서의 화합물, 이의 약학 조성물 및 용도
WO2026108971A1 (fr) * 2024-11-21 2026-05-28 武汉朗来科技发展有限公司 Composé cyclobuténédione, composition pharmaceutique associée et utilisation associée

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
EP0796243B1 (fr) 1994-11-16 1999-01-27 American Home Products Corporation Diaminocyclobutene-3,4-diones
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
EP1551818B1 (fr) * 2002-10-09 2009-02-04 Schering Corporation Thiadiazoledioxydes et thiadiazoleoxides convenant comme ligands des recepteurs des cxc- et cc-chimiokines
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
US7595409B2 (en) 2006-03-31 2009-09-29 Janssen Pharmaceutica N.V. 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers
JP5437061B2 (ja) 2006-05-26 2014-03-12 アッヴィ・インコーポレイテッド ポロ様キナーゼの阻害薬
JP2009542700A (ja) 2006-07-07 2009-12-03 シェーリング コーポレイション Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン
BRPI0810719A8 (pt) 2007-04-30 2016-03-08 Abbott Lab Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
MX2009013276A (es) 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
US20100249439A1 (en) 2007-07-05 2010-09-30 Vincenzo Liotta Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (fr) 2007-07-19 2009-01-22 Wyeth Inhibiteurs de la squarate kinase
EP2173714B9 (fr) 2007-07-24 2013-04-10 Bristol-Myers Squibb Company Dérivés de pipéridine en tant que modulateurs d'activité de récepteur de chimiokine
JP2010534669A (ja) 2007-07-24 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしての非環式誘導体
EP2252327A2 (fr) 2007-12-04 2010-11-24 Schering Corporation Procédés de traitement de la broncho-pneumopathie chronique obstructive
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
WO2010131145A1 (fr) * 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
WO2011058027A2 (fr) 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag Composés de purine n-9-substitués, compositions et procédés d'utilisation
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
WO2013033068A1 (fr) 2011-08-30 2013-03-07 Stephen Martin Courtney Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CA2873984A1 (fr) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibiteurs de l'activite du complexe (iii) de la chaine de transport d'electrons mitochondriale et utilisation de ceux-ci
EP2935249B1 (fr) 2012-12-19 2018-12-12 Novartis AG Inhibiteurs d'autotaxine
EP2948434B1 (fr) 2013-01-25 2017-03-01 Bristol-Myers Squibb Company Dérivés squariques pour le traitement de l'hépatite c
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
PE20211070A1 (es) * 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6

Also Published As

Publication number Publication date
SG11202101827RA (en) 2021-04-29
MY209296A (en) 2025-07-01
UA128700C2 (uk) 2024-10-02
IL281634A (en) 2021-05-31
NI202100012A (es) 2021-06-22
ZA202101169B (en) 2022-07-27
WO2020058869A1 (fr) 2020-03-26
AU2019344107B2 (en) 2022-09-15
US20240368144A1 (en) 2024-11-07
AR116464A1 (es) 2021-05-12
CN112672791B (zh) 2023-10-03
CL2021000683A1 (es) 2021-10-15
EP3852879A1 (fr) 2021-07-28
PH12021550554A1 (en) 2022-02-21
KR102755257B1 (ko) 2025-01-14
TWI754172B (zh) 2022-02-01
CN112672791A (zh) 2021-04-16
US11708360B2 (en) 2023-07-25
CN116874466B (zh) 2026-05-26
US20210206757A1 (en) 2021-07-08
CR20210146A (es) 2021-05-20
US12312344B2 (en) 2025-05-27
KR20230175326A (ko) 2023-12-29
ECSP21018584A (es) 2021-04-29
CA3055805A1 (fr) 2020-03-21
IL281634B1 (en) 2024-10-01
AU2019344107A1 (en) 2021-04-08
JP6989729B2 (ja) 2022-01-05
GEP20237476B (en) 2023-03-27
EA202190586A1 (ru) 2021-07-05
BR112021003956A2 (pt) 2021-05-25
IL281634B2 (en) 2025-02-01
TW202024056A (zh) 2020-07-01
NZ773473A (en) 2023-07-28
CN116874466A (zh) 2023-10-13
PY1978496A (es) 2020-04-20
KR20210046717A (ko) 2021-04-28
US10975065B2 (en) 2021-04-13
DOP2021000045A (es) 2021-04-30
JP2021532166A (ja) 2021-11-25
MX2021003318A (es) 2021-05-14
UY38379A (es) 2020-04-30
CU20210016A7 (es) 2021-10-12
KR102615234B1 (ko) 2023-12-19
US20200095239A1 (en) 2020-03-26
GEAP202215588A (en) 2022-11-10
PE20211070A1 (es) 2021-06-09
CO2021003391A2 (es) 2021-04-08

Similar Documents

Publication Publication Date Title
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
EP3601239A4 (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA53229A (fr) Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
MA51433A (fr) Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1